CytoDyn's Leronlimab Shows Early Promise in Metastatic Colorectal Cancer
Event summary
- CytoDyn presented new Phase 2 data for leronlimab in metastatic colorectal cancer (mCRC) at the AACR Annual Meeting 2026 on April 21, 2026.
- CCR5 expression detected in 100% of 33 evaluable mCRC patients, supporting its therapeutic potential.
- Early biomarker responses showed median circulating tumor DNA (ctDNA) declines of ~70% by week 2 in 19 evaluable patients.
- Combination regimen with TAS-102 and bevacizumab was well tolerated, with no leronlimab-related dose-limiting toxicities observed.
The big picture
CytoDyn's data suggests CCR5 inhibition with leronlimab could enhance immune engagement in mCRC, addressing treatment resistance in a space where standard regimens like TAS-102 plus bevacizumab offer limited durability. The findings build on earlier mTNBC data, positioning CCR5 as a potential cross-tumor target. Success here could validate CytoDyn's platform strategy, but the company must demonstrate consistent clinical benefits to attract partners or investors in this competitive oncology landscape.
What we're watching
- Clinical Validation
- Whether the early biomarker and clinical responses in mCRC can be sustained and translated into meaningful progression-free or overall survival benefits.
- Combination Strategy
- How CytoDyn will leverage these results to position leronlimab as a foundational component in combination regimens for heavily pretreated mCRC patients.
- Regulatory Pathway
- The pace at which CytoDyn can advance leronlimab through later-stage trials and potential regulatory filings based on this emerging data.
Related topics